Omnicell, Inc. (NASDAQ:OMCL) Shares Purchased by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC raised its position in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 4.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,196,990 shares of the company's stock after buying an additional 56,117 shares during the quarter. ArrowMark Colorado Holdings LLC owned approximately 2.58% of Omnicell worth $53,290,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Sumitomo Mitsui Trust Group Inc. raised its stake in shares of Omnicell by 93.3% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company's stock worth $64,573,000 after purchasing an additional 699,925 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Omnicell by 31.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock worth $73,127,000 after acquiring an additional 394,820 shares during the period. Victory Capital Management Inc. lifted its stake in shares of Omnicell by 32.9% in the 4th quarter. Victory Capital Management Inc. now owns 1,526,309 shares of the company's stock worth $67,951,000 after acquiring an additional 377,883 shares during the period. Oberweis Asset Management Inc. purchased a new stake in shares of Omnicell in the fourth quarter valued at about $14,834,000. Finally, Renaissance Technologies LLC raised its holdings in Omnicell by 79.3% during the fourth quarter. Renaissance Technologies LLC now owns 456,343 shares of the company's stock worth $20,316,000 after purchasing an additional 201,831 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Omnicell Trading Down 4.0 %

Shares of OMCL stock traded down $1.03 during mid-day trading on Wednesday, hitting $24.63. 1,626,795 shares of the company's stock were exchanged, compared to its average volume of 547,582. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of 91.23, a PEG ratio of 7.53 and a beta of 0.78. The stock has a 50-day simple moving average of $33.03 and a two-hundred day simple moving average of $40.28. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.75. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.16 by $0.10. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The business had revenue of $269.67 million for the quarter, compared to analyst estimates of $260.18 million. During the same period in the prior year, the firm posted $0.03 EPS. The company's revenue was up 9.5% on a year-over-year basis. Equities analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on OMCL. JPMorgan Chase & Co. lowered their price target on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Wells Fargo & Company dropped their target price on shares of Omnicell from $38.00 to $31.00 and set an "equal weight" rating for the company in a report on Wednesday. StockNews.com cut Omnicell from a "buy" rating to a "hold" rating in a report on Saturday. Finally, Benchmark reduced their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating for the company in a report on Wednesday. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $45.83.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.